Friday, August 12, 2022
HomeWeekly RoundupUK's MHRA issues hydrochlorothiazide safety update

UK's MHRA issues hydrochlorothiazide safety update

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use.

The update says: “Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight and UV rays and to use adequate sun protection.

“Further details of the drug safety update, which includes advice for healthcare professionals, and a letter about the risk and advice sent to prescribers and dispensers of hydrochlorothiazide-containing medicinal products, are available on the MHRA website.”

[link url="https://www.rpharms.com/news/details/MHRA-Drug-Safety-Update-Hydrochlorothiazide-risk-of-non-melanoma-skin-cancer-particularly-in-long-term-use"]RPharms material[/link]
[link url="https://www.gov.uk/drug-safety-update/hydrochlorothiazide-risk-of-non-melanoma-skin-cancer-particularly-in-long-term-use"]Medicines and Healthcare Products Regulatory Agency material[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required